Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 470 (OTCQB: CTABF) (OTC: CSUI), (OTCQX: AVCNF), (TSXV: PCLO) (OTCQX: PCLOF)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC - September 21, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 470 (OTCQB: CTABF) (OTC: CSUI), (OTCQX: AVCNF), (TSXV: PCLO) (OTCQX: PCLOF)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today's podcast we look at a few public company announcements.
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038.
Larry Latowsky, CEO of Canntab said "this is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.
The patent granted is for Canntab's bi-layer or multi-layer tablets consisting of both Instant Release ("IR") and Extended Release ('XR") formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.
Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a 3rd party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations making it the clear delivery choice for doctors, patients or the average consumer.
"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications" continued Latowsky.
In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.
This issued patent covers Canntab's modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.
Canntab has filed applications for 13 patents in Canada and the United States that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis. These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended release tablets, oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.
Cannabis Suisse Corp. (OTC:CSUI), a fully licensed Swiss cannabis cultivation and distribution company for recreational tobacco products and medical CBD oils, announced the company's online expansion plans including the upcoming launch of a new brand on Amazon.
Сannabis Suisse Corp. is developing its own line of products including hemp oil, hemp protein, hemp gummies and hemp hearts with all the appropriate certificates and licenses for sale on Amazon.
This news follows a recent announcement for online distribution of its cannabis and CBD products with uWeed from their retail outlets and online store (www.uweed.ch).
The expansion into online sales of hemp gives the company headquartered in Switzerland, wider access and inroads into the US markets and the legal environment for CBD products evolves.
Mr. Alain Parrik, COO & Director said, " Amazon, is an important distribution outlet for us as we ramp up for expansion across multiple online retail platforms. Introducing a new line of hemp products paves the wave for additional products in the future."
Cannabis Suisse Corp. will be in compliance with Amazon rules and respects their position that CBD is currently banned on Amazon but hemp products are not.
The Company, as a registered manufacturer of both products, will continue to use flowers with the highest concentration of CBD. For the new Amazon product line, oil will be squeezed from the seeds allowing Cannabis Suisse to use the whole plant in its production and benefit from it.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that its advanced RHO Phyto Rapid Act Sprays are now officially available nationwide in Canada on the Medical Cannabis by Shoppers portal, as well as through the Medical Cannabis Real-World Evidence Study at the University Health Network.
Avicanna's RHO Phyto product line is now commercially available after years of research and development through collaborations with world class academic and clinical organizations. The development of RHO Phyto products has focused on the key properties in drug development that health care providers seek when recommending a medical product to their patients such as formulation stability for consistent dosing, enhanced absorption and a range of onset times.
The Rapid Act Spray is a sublingual spray and is among the second set of Avicanna's RHO Phyto products available for purchase through Shoppers. The sublingual sprays bypass first-pass metabolism and are quickly absorbed in the mucosal lining under the tongue. The RHO Phyto Rapid Act Spray provides an alternative delivery form to the RHO Phyto Micro Drops (also available for sale through Shoppers) which are absorbed through the oral route. The RHO Phyto Rapid Act Sprays have been formulated with specific ingredients that enhance absorption and the onset time of cannabinoids across the mucous membrane beneath the tongue. The lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40 (w/w) THC to CBD ratios.
Dr. Justin Grant, Avicanna's Executive Vice President of Scientific Affairs, commented, "The RHO Phyto Rapid Act Sprays are designed for faster onset and can be used in acute conditions where patients seek faster relief. The sublingual sprays can also be used to supplement slower and longer acting products, such as the RHO Phyto Micro Drop, when occasional higher doses may be required. Sublingual administration provides an alternative to the potentially harmful effects of consuming inhalation products."
In August 2020, Avicanna launched its blood orange flavoured RHO Phyto Micro Drop 2:50 CBD and Micro Drop 5:20 CBD. In the coming months, Avicanna will be launching its much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured at MediPharm Labs Inc, a Good Manufacturing Practices ("GMP") certified facility. In addition to strict GMP manufacturing, all RHO Phyto products undergo GMP-level analytical testing by Sigma Analytical Services Inc. and use blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.
Detailed guidelines outlining dosing and titration for Health Care Practitioners ("HCPs") and patients is available on the RHO Phyto website at www.rhophyto.com. In addition, the Avicanna Academy includes additional product information for patients, frequently asked questions, and a recording of Avicanna's 3rd annual symposium which was hosted virtually in partnership with Shoppers on July 21, 2020. For more information visit https://www.avicanna.com/the-avicanna-academy/.
The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as My Cannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care to patients and providing education on the considerations and potential benefits that cannabis has to offer for medical use. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/.
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it has begun sales and distribution of an expanded range of medicinal-grade cannabis extracts cultivated and produced at its Rionegro facilities.
PharmaCielo has been enabled to address customer product inquiries based on technical experience to date combined with increased laboratory and processing capabilities and allowing it to begin commercial production of a significantly expanded range of extract products that began with CBD Isolate and now includes Broad Spectrum Oil, CBD Broad Spectrum Distillate, Water Soluble CBD, CBD Tincture, CBD Distillate Tincture, Full Spectrum Oil Tincture, THC:CBD Formulations and THC Distillate.
"The ability to offer a wide range of bulk products which vary in cannabinoids combination, potency and terpenes content is highly sought-after in the medicinal and wellness sector, as some specific products deliver specific benefits, while others can deliver a full suite of cannabinoid benefits, known as the entourage effect," said David Attard, CEO of PharmaCielo Ltd. "With our different formulations we are also able to provide customers with the flexibility to formulate their final product according to the individual health and drug delivery system needs."
Each of PharmaCielo's extracts are derived from unique and proprietary cultivars developed by the Company's horticultural research experts, optimized for year-round Colombian open-field cultivation, with each extract profile reflecting the unique nature of the cultivar. By example, Broad Spectrum Oil is carefully purified to yield a beautiful amber coloured cannabinoid-rich extract that features multiple cannabinoids, including Cannabidiol (CBD), Cannabidiolic Acid (CBDA), Cannabigerol (CBG), Cannabichromene (CBC), Cannabidivarin (CBDV) and complemented by a range of naturally occurring terpenes including Pinene, Limonene, Linalool, and Myrceneas as part of its attributes.
The expansion of PharmaCielo's product portfolio comes on the heels of a multi-year investment in its processing and extraction capabilities. The Company has begun processing part of its formulations at the expanded facility and is in the position to meet customer demand for commercial volumes at consistent high-quality, purity and potency levels required by healthcare standards.
"As we developed the new product range, based on customer and prospect demand, our team placed a greater emphasis on ensuring we added Water Soluble CBD extract to the mix. The development of this product in particular, will enable PharmaCielo to explore integration opportunities with major players in the health-oriented beverage and topical products segments of the market, which have expressed interest in CBD additives," added Attard.
The Company has begun to accept orders for initial shipments of the new products in the balance of 2020, with continuing production capacity and shipments volumes increasing into 2021. The portfolio of extract products available in commercial volumes appropriate to the global market is expanding on a continuing basis with future additional product introductions expected. Individual product profiles and pricing are available through email@example.com.
Once again, today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI ),is a paid featured company on Investorideas.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android